Xap Therapeutics Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Private

  • Employees
  • 25

Employees

  • Latest Deal Type
  • Early Stage VC

  • Latest Deal Amount
  • $17.9M

  • Investors
  • 3

Xap Therapeutics General Information

Description

Developer of a synthetic biology-driven platform designed for cell therapeutics based in Cambridge. The company's platform applies clustered regularly interspaced short palindromic repeats technology to engineer induced pluripotent stem cells to form the basis of a cell platform producing a "chassis" cell, which is functionalized into cell therapies by genetically engineered constructs, enabling doctors to improve treatment of serious diseases, including autoimmunity and cancer.

Contact Information

Formerly Known As
Rockend
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Babraham Research Campus
  • Maia Building B270
  • Cambridge CB22 3AT
  • England, United Kingdom
Primary Industry
Drug Delivery
Other Industries
Biotechnology
Corporate Office
  • Babraham Research Campus
  • Maia Building B270
  • Cambridge CB22 3AT
  • England, United Kingdom

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Xap Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Early Stage VC 19-Apr-2021 $17.9M Completed Generating Revenue
1. Accelerator/Incubator 01-Jan-2019 Completed Startup
To view Xap Therapeutics’s complete valuation and funding history, request access »

Xap Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Seed Preferred
To view Xap Therapeutics’s complete cap table history, request access »

Xap Therapeutics Patents

Xap Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2024316815-A1 Compositions comprising gpcr based chimeric antigen receptor and methods of use Pending 02-Aug-2023
EP-4754124-A1 Compositions comprising gpcr based chimeric antigen receptor and methods of use Pending 02-Aug-2023
WO-2025027344-A1 Compositions comprising gpcr based chimeric antigen receptor and methods of use Inactive 02-Aug-2023
GB-202311858-D0 Methods and compositions Inactive 02-Aug-2023
AU-2022294190-A1 Methods and compositions Pending 16-Jun-2021 C07K14/705
To view Xap Therapeutics’s complete patent history, request access »

Xap Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Xap Therapeutics Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds
Amplitude Ventures Venture Capital Minority
SR One Corporate Venture Capital Minority
Frame Shift Bio-Incubator Accelerator/Incubator
To view Xap Therapeutics’s complete investors history, request access »

Xap Therapeutics FAQs

  • When was Xap Therapeutics founded?

    Xap Therapeutics was founded in 2017.

  • Where is Xap Therapeutics headquartered?

    Xap Therapeutics is headquartered in Cambridge, United Kingdom.

  • What is the size of Xap Therapeutics?

    Xap Therapeutics has 25 total employees.

  • What industry is Xap Therapeutics in?

    Xap Therapeutics’s primary industry is Drug Delivery.

  • Is Xap Therapeutics a private or public company?

    Xap Therapeutics is a Private company.

  • What is the current valuation of Xap Therapeutics?

    The current valuation of Xap Therapeutics is .

  • What is Xap Therapeutics’s current revenue?

    The current revenue for Xap Therapeutics is .

  • How much funding has Xap Therapeutics raised over time?

    Xap Therapeutics has raised $17.9M.

  • Who are Xap Therapeutics’s investors?

    Amplitude Ventures, SR One, and Frame Shift Bio-Incubator have invested in Xap Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process